Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14.

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

Collaborators (133)

Cahn P, Patterson P, Zala C, Krolewiecki A, Ochoa CE, Parenti P, Suarez C, Losso M, Ivalo S, Duran A, Lourteau L, Toibaro J, Cassetti I, Vanzulli C, Laurido M, Bugarin G, Trinidad G, Urueña A, Bologna R, Benetucci J, Timerman A, Vipich R, Tardochi S, Furtado J, Madruga JV, Noguiera R, Leme S, Estevam D, Ramalho M, Araujo F, Fonsi M, Franco E, Sartio R, Silveira M, Monteiro D, Carvalho M, Resende M, de Moraes M, Abreu W, Krzesinski AL, da Cunha CA, Reis R, Rocha J, Kuchiki M, Toledo P, De Rossi S, Carvalho M, da Silva M, Grinsztejn B, Ribeiro J, Pilotto J, Silva A, Rodrigues J, Friedman R, Rolla V, Hoagland B, Vorsatz C, Barros M, Cardoso S, Villanueva JA, Chávez G, Gonzalez LA, Amador F, Vinogradova E, Zakharova N, Vinogradova A, Leonova O, Krutitskaya L, Badosova N, Semushina Y, Yakovlev A, Burova N, Abrosimova L, Kingo Z, Moshkovich G, Minaeva S, Goryaeva M, Kozyrev O, Malyuzhenko I, Malyuzhenko M, Romanenko O, Makarova M, Zamyatina E, Siraziyeva F, Mikusev R, Koksin V, Shoshokin V, Mohapi L, Khosa M, Mohohlo D, Ive P, John MA, Rubel D, Sanne I, Firnhaberr C, Spencer D, Marshall J, Raniga M, Baraldi E, Itturalde M, Podzamczer D, Corbera E, Plaza M, Guillen P, Fuster M, Sambeat MA, García G, Cadafalch J, Macià Mdel M, Aguirrebengoa K, Goicoetxea J, Montejo M, Gil Ide L, Gómez RC, Sanz J, Ungsedhapand C, Duncomb C, Ananworanich J, Autar S, Avihingsanon A, Bunupuradah T, Hay P, Velisetty P, Macallan D, Sadiq T, Lau R, Brennan-Benson P, Pakianathan M, Mantell J, Gazzard B, Maitland D, Jackson A, Teague A.

Author information

  • 1HIV-NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. kiat.r@chula.ac.th

Abstract

OBJECTIVES:

TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients.

METHODS:

Patients were randomized to TMC125 800 mg twice a day (bid) (phase II formulation; n=59) or the control PI (n=57), plus two nucleoside reverse transcriptase inhibitors (NRTIs).

RESULTS:

In an unplanned interim analysis, patients receiving TMC125 demonstrated suboptimal virological responses relative to the control PI. Therefore, trial enrolment was stopped prematurely and TMC125 treatment discontinued after a median of 14.3 weeks. In this first-line NNRTI-failure population, baseline NRTI and NNRTI resistance was high and reduced virological responses were observed relative to the control PI. No statistically significant relationship was observed between TMC125 exposure and virological response at week 12. TMC125 was better tolerated than a boosted PI for gastrointestinal-, lipid- and liver-related events.

CONCLUSIONS:

In a PI-naïve population, with baseline NRTI and NNRTI resistance and NRTI recycling, TMC125 was not as effective as first use of a PI. Therefore the use of TMC125 plus NRTIs alone may not be optimal in PI-naïve patients with first-line virological failure on an NNRTI-based regimen. Baseline two-class resistance, rather than pharmacokinetics or other factors, was the most likely reason for suboptimal responses.

PMID:
18795960
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk